Clinical Laserthermia Systems

Katarina Lundqvist assumes the role as Interim CFO as of 18 September 2023. As announced on 8 September, Rolf Ho Bornschein has decided to leave his role as CFO at CLS. He will remain with the company during his notice period, or no longer than to 25 November, and he will meanwhile assist the company during the transition period.

Katarina Lundqvist, who currently is a Financial Consultant at MPYA Finance, has previously held senior positions at life science companies active in global markets. Most recently she was Nordic Finance Director at Ferring Pharmaceuticals, and before that Finance Manager at Jolife, owned by the American medtech company Stryker. Katarina has also been Finance Manager at Tunstall, and CFO at Setterwalls Advokatbyrå, a law firm in Malmö, Sweden.

“We are proud to have Katarina as interim CFO and as a member of the management team during the recruitment period for a permanent CFO. She has extensive experience from pharmaceutical and medtech companies with international businesses and I am sure that she will bring great value to our finance operations and the company. We are also glad that Rolf will remain and work closely with Katarina during the Fall to secure continuity,” says Dan J. Mogren, CEO, CLS.

The information was submitted for publication, through the agency of the contact person set out below on 18 September 2023, at CEST 08:40.

Contact Information:


Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 – (0)705 – 90 11 40

E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.

For more information about CLS, please visit the Company's website: www.clinicallaser.se